– USA, CA – Inspyr Therapeutics, Inc. (OTC:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced today the appointment of Richard Buller, M.D., Ph.D. to its Board of Directors.
“We are excited to have Rich join the Board as his extensive experience in the development of novel oncology therapeutics will very valuable as we plan for additional clinical studies for our lead oncology therapeutic Mipsagargin,” said Chris Lowe, Inspyr’s President and Chief Executive Officer. “With a career built at leading oncology companies such as Pfizer, Exelixis, and GSK and earlier in clinical research, Rich’s background makes him uniquely qualified to share expertise in how to successfully develop novel therapeutics for patients with cancer.”
Richard Buller, M.D., Ph.D. has over 25 years of experience leading the development of novel oncology products, resulting in 15 regulatory submissions for 8 oncology drug products as well as 2 premarketing approvals for companion diagnostics. In his most recent positions, Dr. Buller served initially as Vice President of Translational Oncology, adding a brief role as Interim Head of Late-Stage Clinical Development, and then became Pfizer’s Head of Oncology Clinical Development. Previously, he was Vice President, Translational Medicine for Exelixis and was a member of the Joint Development Committees with partners Bristol Myers Squibb and Sanofi Aventis. Earlier, he was Director, Oncology Medicine Development Center at GSK. Dr. Buller also has 13 years of direct experience in clinical and laboratory oncology research, holding positions of increasing responsibility including 10 years as Division Director of Gynecologic Oncology at the University of Iowa Hospitals and Clinics. He has been recognized as one of America’s Top Physicians on multiple occasions. Dr. Buller was awarded a Doctor of Medicine from Baylor College of Medicine, with honors. He earned a Bachelor of Science from the University of California Los Angeles (UCLA), graduating summa cum laude with honors in chemistry, where he was selected to receive the 2016 UCLA Chemistry and Biochemistry Alumni Award.
About Inspyr Therapeutics
Inspyr Therapeutics, Inc. is developing a novel technology platform that combines a powerful therapeutic with a patented prodrug delivery system that targets the release of drugs within solid tumors. Mipsagargin, its lead drug candidate, has been studied in a Phase 2 clinical trial in patients with advanced hepatocellular carcinoma and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. Mipsagargin is currently being evaluated in Phase 2 clinical studies in patients with glioblastoma, prostate cancer, and clear cell renal cancer.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
